Curium Further Expands European Availability of PYLCLARI – an Innovative 18F-PSMA PET Radiopharmaceutical Indicated in Patients with Prostate Cancer
Curium, a world leader in nuclear medicine, today announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now ...
Pharmabiz12d
Curium introduces innovative 18F-PSMA PET radiopharmaceutical, Pylclari to treat prostate cancer in Estonia, Finland, Latvia, & Sweden
Curium introduces innovative 18F-PSMA PET radiopharmaceutical, Pylclari to treat prostate cancer in Estonia, Finland, Latvia, & Sweden: Paris, France Wednesday, January 29, 2025, ...
Finanznachrichten11d
Curium Expands European Supply of Iodine-131 Diagnostic Capsules with New Partnership Agreement with Izotop
PARIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has expanded its existing partnership with Institute of Isotopes Co. Ltd. (Izotop ...
Finanznachrichten13d
Curium Further Expands European Availability of PYLCLARI - an Innovative 18F-PSMA PET Radiopharmaceutical Indicated in Patients with Prostate Cancer
PARIS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine ... prostate cancer is one of the most common cancers among men with around 25,000 new cases diagnosed ...